The paradox of rare diseases is that any single diagnosis affects a small number of individuals, but 6% to 8% of the world population is afflicted.
1 This fact renders rare diseases both difficult to study and a significant public health concern. Even basic epidemiologic studies of rare diseases are challenging given the heterogeneous, progressive clinical course of the rare disease and the geographic dispersion of patients.
2 Geographic distribution requires an extensive recruitment and monitoring infrastructure, dramatically increasing the cost and time required for participant accrual. These barriers, coupled with small markets, reduce incentives for the pharmaceutical industry and funders to support rare disease research,
3 constrain evidence, and result in clinical practice variation and inconsistent patient outcomes.